OOIR: Observatory of International Research

Papers

(The H4-Index of Gut is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Defining the key intrahepatic gene networks in HCV infection driven by sex	1697
Picking up microbial clues in early-onset colorectal cancer	1455
Hepatocyte senescence in alcohol-associated hepatitis: epiphenomenon or disease-driving mechanism?	966
Correction:P97 A patient information bundle outlining dietary advice in liver disease specific to the cost of living crisis improves patient care: ‘Looking after Your Liver for Less’	460
Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus	329
S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos	321
Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system	222
Third Asia-Pacific consensus recommendations on colorectal cancer screening and postpolypectomy surveillance	220
Current therapies and new developments in NASH	203
Unusual history of ‘stitch’	202
Response to McAlindon’s letter	200
Finding a mate for MLCK: improving the potential for therapeutic targeting of gut permeability	200
Innumerable nodules in all parts of the small intestine	198
Growth rates and histopathological outcomes of small (6–9 mm) colorectal polyps based on CT colonography surveillance and endoscopic removal	188
Crohn’s disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset	180
Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges	178
IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells	171
HBcrAg values may predict virological and immunological responses to pegIFN-a in NUC-suppressed HBeAg-negative chronic hepatitis B	170
Impact of margin thermal ablation after endoscopic mucosal resection of large (≥20 mm) non-pedunculated colonic polyps on long-term recurrence	169
Genetically proxied ketohexokinase function and risk of colorectal cancer: a Mendelian randomisation study	168
Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?	164
Reassessing the prophylactic effect of clip closure to prevent delayed rebleeding after colorectal endoscopic submucosal dissection	162
Gut virome-colonisingOrthohepadnavirusgenus is associated with ulcerative colitis pathogenesis and induces intestinal inflammationin vivo	161
Liquid biopsy to identify Barrett’s oesophagus, dysplasia and oesophageal adenocarcinoma: theEMERALDmulticentre study	151
A mucus production programme promotes classical pancreatic ductal adenocarcinoma	151

Absence of a pancreatic microbiome in intraductal papillary mucinous neoplasm	150
COVID-19 and liver disease	149
Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis	148
Rate of suitable cases for primary EUS-guided biliary drainage in distal malignant biliary obstruction	146
Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study	143
Where are we with gastric cancer screening in Europe in 2024?	139
Methionine deficiency facilitates antitumour immunity by altering m⁶A methylation of immune checkpoint transcripts	137
Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?	134
Perplexing case of abdominal pain with eosinophilia and fasciitis	131
Selective decontamination of the digestive tract in critically ill children: fighting fire with fire or burning down the house?	130
Association between appendectomy and Parkinson’s disease from the UK Biobank	126
Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer	121
Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment	115
Correction: Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	115
Rare cause of obstructive jaundice	114
Endoscopic mucosal and submucosal cutting for long benign oesophageal strictures	114
GI highlights from the literature	113
Tiny contributors to severe obesity inside the gut	110
Shaggy white lesion with morphological changes in the oesophagus	108
Lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis: more doubts than answers	107
Unveiling 8 years of duodenoscope contamination: insights from a retrospective analysis in a large tertiary care hospital	105
Discovery of the pancreatic basal cell: a new candidate for an adult stem cell emerges	105
Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19	105
Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model	103
Tumour-intrinsic alterations and stromal matrix remodelling promote Wnt-niche independence during diffuse-type gastric cancer progression	103
New entity of adult ultra-short coeliac disease: the first international cohort and case–control study	102
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance	102
Asian Pacific Association of Gastroenterology task force recommendations on surveillance for Helicobacter pylori associated gastric premalignant conditio	102
Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD	101
Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies	101
Impact of climate change on vulnerable populations	100
24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T_H17 pathogenicity and transdifferentiation	99
Humoral response to SARS-CoV-2 infection among liver transplant recipients	98
Intron-mediated enhancement of SPINK1 expression for pancreatitis therapy	97
Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma	96
Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma	95
Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling	94
MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression	91
Need for standardised approaches to human microbiome research using the example of colorectal neoplasia research	91
British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy	89
Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD	87
Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression	85
Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?	85
Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity	83
SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination	81
Association between inflammatory bowel disease and Alzheimer’s disease: multivariable and bidirectional Mendelian randomisation analyses	81
Endoscopic stratification of gastric intestinal metaplasia: where are we, where do we want to go and how do we get there?	81
Treatment of type 2 diabetes with MASLD: new evidence for personalised medicine	80
Reply: Prevalence of serum HBsAg <100 IU/mL in inactive chronic hepatitis B	79
Environmental and healthcare trade-offs between single-use and reusable gastroscopes	79

SMYD2-mediated methylation of STAT1 protects against hepatic ischaemia/reperfusion injury by blocking JAK-STAT1 signalling pathways	76
GI highlights from the literature	76